Boston Scientific BSX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.56B+75.8% | $2.89B+56.7% | $2.78B+55.8% | $2.5B+37.0% | $2.02B+14.3% | ||
| $1.39B+8.1% | $1.37B+7.8% | $1.35B+9.5% | $1.32B+7.1% | $1.29B+6.2% | ||
| $308M+11.2% | $299M+12.4% | $297M+16.0% | $286M+15.8% | $277M+14.9% | ||
| $279M-18.9% | $269M-23.4% | $261M-22.1% | $262M-14.1% | $344M+29.3% | ||
| —— | —— | —— | —— | —— | ||
| $169M— | $296M— | $396M— | —— | —— | ||
| —— | —— | —— | $66M+106% | -$1M-102% | ||
| $4.34B+13.9% | $4.53B+32.0% | $4.63B+57.6% | $4.29B+62.8% | $3.81B+53.9% | ||
| $866M+8.5% | $876M+10.9% | $802M+2.8% | $800M+1.1% | $798M+2.4% | ||
| $1.88B-61.2% | $1.59B-65.7% | $4.92B+144% | $5.79B+552% | $4.83B+226% | ||
| -$2.73B+53.7% | -$2.64B+53.6% | -$5.83B-92.1% | -$6.76B-274% | -$5.9B-149% | ||
| -$888M-286% | -$395M-122% | $3M-99.8% | $114M— | $478M— | ||
| $5M— | $44M— | $32M— | —— | —— | ||
| —— | —— | —— | —— | -$1.58B-191% | ||
| —— | $319M+27.6% | $301.75M+19.6% | $284.5M+11.8% | $267.25M+4.1% | ||
| —— | $561M-14.5% | $584.75M-5.7% | $608.5M+4.2% | $632.25M+15.4% | ||
| -$17M0.0% | $18M+460% | $10M-9.1% | -$24M-152% | -$17M-127% | ||
| -$394M— | -$2M— | -$60M— | —— | —— | ||
| —— | —— | —— | $158M+326% | -$105M-250% | ||
| —— | —— | —— | —— | —— | ||
| $53M-59.8% | $132M+159% | $178M— | $169M+5,533% | $132M+2,100% | ||
| -$129M-579% | -$84M-265% | -$17M+45.2% | -$18M+45.5% | -$19M+45.7% | ||
| $116M-60.1% | $254M-9.3% | $196M-25.8% | $251M+61.9% | $291M+101% | ||
| $222M— | $258M— | —— | —— | —— | ||
| $98M-22.8% | $131M+50.6% | $132M+55.3% | $130M+54.8% | $127M+51.2% | ||
| —— | —— | —— | —— | —— | ||
| $20M+286% | $7M+800% | -$2.25M+88.8% | -$1.5M+96.2% | -$10.75M+81.5% | ||
| —— | —— | —— | —— | -$5M-25.0% | ||
| $248M-6.4% | $282M+22.6% | $290M+32.4% | $271M+36.9% | $265M+33.2% | ||
| $771M— | $1.6B— | —— | —— | —— | ||
| —— | $119M+1.7% | $118.5M— | $118M— | $117.5M— | ||
| $3.48B+15.3% | $3.66B+38.3% | $3.82B+77.4% | $3.49B+89.3% | $3.01B+77.5% | ||
| $3.48B+15.3% | $3.66B+38.3% | $3.82B+77.4% | $3.49B+89.3% | $3.01B+77.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Boston Scientific generate?
- Boston Scientific (BSX) generated $4.3B in operating cash flow over the trailing twelve months.
- What is Boston Scientific's free cash flow?
- After $866.0M of capital expenditures, Boston Scientific's free cash flow was $3.5B over the trailing twelve months, up 15.3% year over year.
- Where does Boston Scientific's cash flow data come from?
- Every line is extracted from Boston Scientific's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
